Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 44,326 staff and has a market cap (total outstanding shares value) of USD$163.1 billion.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$73.8 |
---|---|
52-week range | USD$48.1852 - USD$73.92 |
50-day moving average | USD$68.6947 |
200-day moving average | USD$67.7388 |
Wall St. target price | USD$74.08 |
PE ratio | 28.6678 |
Dividend yield | USD$1.04 (1.47%) |
Earnings per share (TTM) | USD$2.462 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $73.8 from 2020-12-18
1 week (2021-01-07) | 5.29% |
---|---|
1 month (2020-12-17) | 2.89% |
3 months (2020-10-15) | 4.58% |
6 months (2020-07-15) | 10.83% |
1 year (2020-01-15) | 18.29% |
---|---|
2 years (2019-01-15) | 56.36% |
3 years (2018-01-13) | N/A |
5 years (2016-01-15) | 38.93% |
Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Novo Nordisk A/S shares trade at around 29x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.8731. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gross profit TTM | USD$102.5 billion |
---|---|
Return on assets TTM | 26.33% |
Return on equity TTM | 73.83% |
Profit margin | 32.65% |
Book value | $3.077 |
Market capitalisation | USD$163.1 billion |
TTM: trailing 12 months
There are currently 4.1 million Novo Nordisk A/S shares held short by investors – that's known as Novo Nordisk A/S's "short interest". This figure is 27.8% down from 5.7 million last month.
There are a few different ways that this level of interest in shorting Novo Nordisk A/S shares can be evaluated.
Novo Nordisk A/S's "short interest ratio" (SIR) is the quantity of Novo Nordisk A/S shares currently shorted divided by the average quantity of Novo Nordisk A/S shares traded daily (recently around 995992.70072993). Novo Nordisk A/S's SIR currently stands at 4.11. In other words for every 100,000 Novo Nordisk A/S shares traded daily on the market, roughly 4110 shares are currently held short.
However Novo Nordisk A/S's short interest can also be evaluated against the total number of Novo Nordisk A/S shares, or, against the total number of tradable Novo Nordisk A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novo Nordisk A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Novo Nordisk A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Novo Nordisk A/S shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novo Nordisk A/S.
Find out more about how you can short Novo Nordisk A/S stock.
Dividend payout ratio: 48.37% of net profits
Recently Novo Nordisk A/S has paid out, on average, around 48.37% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.47% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.47% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $1.04 per share.
While Novo Nordisk A/S's payout ratio might seem fairly standard, it's worth remembering that Novo Nordisk A/S may be investing much of the rest of its net profits in future growth.
Novo Nordisk A/S's most recent dividend payout was on 25 August 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 August 2020 (the "ex-dividend date").
Novo Nordisk A/S's shares were split on a 5:1 basis on 9 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.
Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $48.1852 up to $73.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.3163. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.